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Abstract: Birdshot chorioretinopathy is a relatively uncommon subtype of idiopathic  posterior 
uveitis with distinct clinical characteristics and a strong genetic association with the Human 
Leukocyte Antigen (HLA)-A29 allele. The diagnosis remains clinical and is based on the pres-
ence of typical clinical features, including multiple, distinctive, hypopigmented choroidal lesions 
throughout the fundus. The long-term visual prognosis of this disorder, however, remains guarded – 
central visual acuity can be preserved until late in the disease and it is not uncommon for patients 
to receive inadequate immunosuppressive treatment, leading to a poor long-term outcome in which 
peripheral retinal damage eventually leads to visual deterioration. Birdshot chorioretinopathy has 
proven a particularly attractive area of study within the field of uveitis, as it is a relatively easily 
defined disease with an associated human leukocyte antigen haplotype. Despite this, however, the 
immune mechanisms involved in its pathogenesis remain unclear, and some patients continue to 
lose retinal function despite therapy with corticosteroids and conventional immunosuppressive 
agents. Laboratory research continues to investigate the underlying mechanisms of disease, and 
clinical research is now being driven to improve the phenotyping and monitoring of this condi-
tion as, in the era of so-called personalized medicine, it is becoming increasingly important to 
identify patients at risk of visual loss early so that they can be treated more aggressively with 
targeted therapies such as the newer biological agents. This approach requires the formation of 
collaborative groups, as the relative rarity of the condition makes it difficult for one center to 
accumulate enough patients for worthwhile studies. Nevertheless, results obtained with newer 
therapies, such as biological agents directed against particular cytokines or cell-surface receptors, 
demonstrate ever improving control of the inflammation in refractory cases, providing hope that 
the outlook for visual function in this condition can only improve.
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Introduction
Birdshot chorioretinopathy (BSCR), also known as birdshot retinochoroiditis, is 
an uncommon type of idiopathic bilateral posterior uveitis that is typically seen in 
patients of Caucasian origin in their 6th decade of life and which has a strong genetic 
association with the human leukocyte antigen HLA-A29.1 It is responsible for 6%–8% 
of cases of posterior uveitis, and the clinical presentation is usually one of a gradual 
deterioration of vision associated with the presence of floaters.2 The condition has a 
distinct clinical phenotype consisting of mild anterior uveitis, but moderate vitritis 
and/or vitreous debris, retinal vasculitis, and characteristic multiple hypopigmented 
cream-colored, irregularly shaped choroidal lesions that are often clustered around 
the optic disc (Figure 1A–C).2
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BSCR is generally considered to be an isolated ocular 
disorder,3 despite a few reports in the literature describ-
ing its possible association with systemic illnesses includ-
ing essential hypertension, cerebrovascular accidents, 
hearing loss, and cutaneous immune-mediated conditions 
such as vitiligo and psoriasis.4–8 Its pathogenesis, however, 
remains unclear, and this has contributed to a lack of optimal 
treatment protocols. The natural history of BSCR is of a 
chronic and progressive disorder – the majority of patients 
develop chronic disease with progressive retinal dysfunction, 
although a smaller proportion do have limited disease with 
spontaneous remission of their intraocular inflammation.1,2 
Central retinal function can be preserved until quite late in the 
disease, leading to a false impression of disease quiescence 
and thus inadequate immunosuppression being introduced, 
potentially prejudicing the long-term visual prognosis.
The diagnosis of BSCR is often reinforced by testing for 
the HLA-A29 haplotype, but it remains a clinical one: the 
positive predictive value of HLA-A29 testing is less than 50% 
in the posterior uveitis population, owing to some 8% of the 
general population being HLA-A29-positive.9 Internation-
ally accepted criteria for the diagnosis of BSCR are based 
on the presence of bilateral mild intraocular inflammation, 
“birdshot lesions,” and the absence of keratic precipitates 
and posterior synechiae.1
BSCR has proven particularly attractive to study within 
the field of uveitis, as it is a relatively easily defined disease 
with an associated human leukocyte antigen haplotype. The 
immune mechanisms involved in its pathogenesis remain 
unclear, however, and laboratory research continues to inves-
tigate the underlying mechanisms of disease. The advent of 
therapeutic biological agents targeted at particular cytokines 
and molecular pathways has also exposed our lack of knowl-
edge of both the pathogenetic mechanisms of disease as well 
as how to accurately assess disease activity and response to 
treatment. Accurate phenotyping is particularly important for 
early identification of patients at risk of visual loss, such that 
they can be treated more aggressively with targeted therapies, 
which may themselves carry an increased side effect profile 
that needs adequate justification for use. This is particularly 
key, as a significant proportion of patients continue to lose 
retinal function despite therapy with corticosteroids and 
conventional immunosuppressive agents.2
Disease pathogenesis
Despite the strong association of HLA-A29 allele with 
BSCR, such that 85%–95% of affected patients carry the 
HLA-A29 haplotype,1,9 the pathogenesis of BSCR remains 
largely unknown.10 Evidence for the role of HLA-A29 in 
the development of BSCR originates from observations that 
transgenic mice either expressing HLA-A29 or injected with 
human HLA-A29.2-purified cDNA develop spontaneous 
bilateral posterior uveitis reminiscent of human BSCR.11,12 
Sequences from retinal soluble antigen also bind efficiently 
to HLA-A29,13 and in vitro responsiveness to retinal soluble 
antigen can be demonstrated in a high proportion of BSCR 
patients;14 however, nearly 8% of the Caucasian population 
is HLA-A29-positive, and the vast majority of these people 
do not develop BSCR.1,9 It has therefore been theorized that 
molecular mimicry triggered by prior microbial infection 
could play a direct role in triggering the disease,15 although 
there remains a lack of conclusive evidence for a direct asso-
ciation between any microbiological infection and BSCR.16
A role of T-cells in disease pathogenesis has been sug-
gested by both histopathology17 and the efficacy of anti-T-cell 
agents such as cyclosporine A,18 and recent attention is 
now focusing on the more recently described Th17 system. 
Upregulated Th17 responses and increased interleukin (IL)-
17 production from T-cells have previously been associated 
with chronic inflammation in gut disease19 as well as other 
human leukocyte antigen class I-related diseases.20
Increased IL-17 levels have also been demonstrated in 
the aqueous humor of eyes with BSCR,21 and increased 
serum IL-17, IL-23, and transforming growth factor-
beta 1 levels have also been found to be raised in some 
treatment-naïve patients with BSCR.22 Taken together, these 
findings are suggestive of an organ-specific Th17-driven 
A B
C
Figure 1 Fundus photographs (A-C) of patients with HLA-A29 positive birdshot 
chorioretinopathy demonstrating heterogeneity of fundal appearances.
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autoimmune  process,22 factors important in Th17 cell dif-
ferential being found in the serum, and the effector cytokine 
of Th17 cells, IL-17, being found in intraocular fluid. This 
may help to direct treatment away from nonspecific T-cell 
blockade, although the IL-17 inhibitor secukinumab failed 
to demonstrate efficacy in uveitis in its initial clinical  trials.23 
Further trials in more selected patient populations are, 
 however, planned.23
Monitoring disease activity  
and response to treatment
As our knowledge of the pathogenesis of uveitis in general 
improves, this presents increasing opportunities for targeted 
treatment and early intervention.24 One of the major goals of 
therapy has to be the early identification of patients at risk of 
a poor outcome, so that intervention can be targeted at this 
group in a more aggressive fashion. In order to achieve this, 
however, improved disease phenotyping, early detection of 
disease progression, and rapid assessment of any response 
to treatment are all required.
It is characteristic of patients with BSCR to complain 
of poor quality of vision despite often having good best-
corrected distance visual acuity until late in the disease.25 
Symptoms including nyctalopia, loss of contrast sensitivity, 
and color vision defects are common,26 and abnormalities in 
color discrimination, predominantly in the blue–yellow spec-
trum, are also very common complaints, occurring in almost 
two-thirds of patients.4 These findings suggest that simply 
monitoring distance visual acuity is probably not sufficient 
to assess visual function or monitor disease progression in 
this disorder, even though retrospective studies suggest a 
significant association between visual acuity at the onset of 
the disease and long-term visual outcome.8,24
Biomicroscopically visible ocular features of disease 
severity or chronicity, such as hyperpigmentation of the bird-
shot lesions27 or the development of choroidal neovascular 
membranes (Figure 2),2,8 also tend to occur too late in the 
disease process to be useful markers of disease progression. 
Attention has therefore been directed for some time at other 
investigational modalities, to see whether these can detect 
disease progression earlier and more reliably, allowing for 
the early identification of at-risk patients.
imaging of the retinal  
and choroidal circulations
Fundus fluorescein angiography remains the gold-standard 
assessment of the integrity of the retinal vasculature, but it has 
relatively low specificity in characterizing birdshot lesions, 
especially in the early stages of the disease when the overly-
ing retinal pigment epithelium is unaffected. Nevertheless, 
it remains a useful tool for the assessment of disease activity 
and its complications, including the presence of CMO and 
retinal vasculitis (Figure 3A and B).5,28,29 Indocyanine green 
angiography is probably more sensitive,30 and the fundus 
lesions tend to show different characteristics at different 
stages of the disease, making indocyanine green angiography 
one of the currently preferred methods of monitoring disease 
activity and response to treatment.30
While not directly imaging the retinal or choroidal cir-
culation, autofluorescence provides a further camera-based 
imaging modality that is used in some centers to monitor 
patients with BSCR,31,32 although there is as yet little evidence 
regarding its prognostic value.
Optical coherence tomography  
scanning
Macular edema occurs in up to 50% of patients with 
BSCR (although there is considerable variability in its 
Figure 2 A patient with long-standing birdshot chorioretinopathy who developed 
a central choroidal neovascular membrane associated with a dramatic drop in visual 
acuity.
A B
Figure 3 Fundus fluorescein angiograms demonstrating (A) central and (B) 
peripheral retinal vasculitis associated with birdshot chorioretinopathy.
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reported  prevalence), and it is the commonest cause of 
visual loss.29,33,34 Optical coherence tomography (OCT) is 
the favored method by which to quantify retinal thickness 
and treatment response,33,35 although there is still some con-
troversy regarding the correlation between OCT and fundus 
fluorescein angiography findings.33,36 However, more recent 
data suggests that retinal thinning is also an important associ-
ation of visual deterioration, which may complicate analyses 
of central macular thickness. Gradual thinning of the outer 
retina occurs in the late stages of BSCR37 and is associated 
with significantly lower visual acuities.40 Subtle changes in 
the macular architecture, such as the loss of a linear band of 
high reflectivity corresponding to the photoreceptor layer, 
may also be related to abnormal visual function.33,36
Extramacular enhanced depth OCT scanning is a newer 
technique in which high resolution visualization of the chor-
oidal anatomy is possible. Rather than focusing on the central 
retina, the analysis algorithms are adjusted to enable pen-
etration into deeper layers of the choroidal anatomy, and the 
scanner can be directed at more peripheral retinal locations.39 
Recent evidence from patients with BSCR suggests that focal 
loss of the inner segment/outer segment junction can be 
detected, together with thinning of specific choroidal vascu-
lar layers.39 This may prove useful in detecting extramacular 
disease progression and response to treatment, although data 
are currently limited and further studies are required.
electrodiagnostic testing
Abnormal electrophysiological retinal responses were described 
in some of the earliest reports of BSCR,40 and electrodiagnostic 
testing has become one of the most important tools in the man-
agement of patients with BSCR. It allows for the early detection 
and objective monitoring of subtle functional retinal changes 
ahead of changes in clinical phenotype that herald irreversible 
loss of visual function.41,42 Electroretinography typically reveals 
a disproportionate decrease in b-wave amplitude compared with 
a-wave amplitude in the early stages of the disease, suggesting 
neural retinal dysfunction with relative outer retinal sparing,41,42 
which has been suggested to be related to inner retinal dysfunc-
tion secondary to retinal vasculitis.43
Photoreceptor dysfunction usually occurs later in the dis-
ease, and rod dysfunction usually precedes cone dysfunction, 
detectable by relative changes in the scotopic and photopic 
b-waves.41 Nevertheless, delayed 30 Hz cone flicker implicit 
time appears to be the most sensitive and consistently affected 
electrophysiological parameter.42,44 It has been demonstrated 
to correlate well with disease activity and might be useful in 
predicting treatment failure.44,45
Electrophysiological testing is, however, time-consuming 
and requires experienced operators to obtain consistent 
results, limiting its repeatability and general applicability.
Perimetry
A large range of different visual field defects have been 
described in the literature, including generalized diminished 
sensitivity, peripheral constriction, and/or small islands of 
paracentral scotomas, which appear not to be correlated 
with the birdshot lesion, as well as blind-spot enlargement.4 
Despite a lack of consistency in visual field assessment 
between different study groups, it is clear that extensive 
visual field deterioration can coexist with relatively well-
preserved good central visual acuity, and that these changes 
may precede other clinical symptoms.46 Furthermore, visual 
field assessment may also be useful in monitoring response 
to treatment in these patients.46,47 This does suggest a role 
for perimetry as an adjunct to visual acuity testing alone 
in the detection of disease activity, but it may not be sensi-
tive enough to detect early evidence of disease progression. 
Microperimetry has been thought to provide more sensitive 
assessments in some macular diseases, but there is again 
limited evidence for its use in BSCR.48
Treatment
As with noninfectious uveitis in general, corticosteroids 
remain the mainstay of therapy in BSCR due to their 
strong and rapid anti-inflammatory and immunosuppres-
sive effects.49 As the disease is usually bilateral, these tend 
to be administered orally rather than locally, starting at a 
high dose followed by a slow taper. Owing, however, to the 
chronic nature of the disease and slow decline in visual and 
retinal function in the absence of adequate immunosuppres-
sion, early introduction of second-line immunosuppressive 
agents appears to be beneficial in preserving visual func-
tion and in minimizing side effects from higher doses of 
corticosteroids.45,50,51
Conventional second-line 
immunosuppression
Although the pathogenesis of BSCR remains incompletely 
understood, evidence of T-cell-mediated responses has sup-
ported the use of cyclosporine in patients for whom low-dose 
prednisolone is insufficient to control their intraocular inflam-
mation;47 however, problems with renal impairment and 
hypertension limit the drug’s usefulness.18,45,52  Antimetabolite 
agents such as azathioprine, methotrexate, and mycopheno-
late mofetil have all been used as steroid-sparing agents to 
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treat patients with BSCR with varying degrees of success, 
either separately50 or in combination.53
established biologic agents
In contrast to immunosuppressive agents, biologic agents 
modulate inflammation by targeting specific receptors or 
single molecules and thus offer a more specific targeted 
suppression of immune effector response and tissue damage. 
They have been shown to be a useful alternative in patients 
who failed to respond to conventional immunosuppressive 
therapy,54,55 but there is also evidence that their use can reduce 
the risk of visual loss in severe forms of intraocular inflam-
mation, such as uveitis related to Behcet’s disease.56
The greatest volume of evidence for the biological agents 
exists for the tumor necrosis factor (TNF)-alpha inhibitors. This 
molecule has been detected in human eyes with a variety of 
inflammatory conditions and it plays a key role in the regulation 
of the inflammatory process seen in experimental autoimmune 
uveitis in rodents.57 Inhibition of TNF-α results in a decrease in 
adhesion molecules and proinflammatory cytokines as well as in 
regulation of chemokine levels. The use of anti TNF-α antibod-
ies can be effective in both short- and long-term management 
of patients with refractory posterior uveitis.58,59
Infliximab, a chimeric monoclonal antibody targeted 
against TNF-α, can be very effective in the treatment of 
patients with different types of refractory uveitis, including 
those with BSCR.60–62 In the largest series to date of patients 
with BSCR treated with infliximab, nearly 90% of patients 
achieved complete control of inflammation after 1 year of 
treatment.63 Furthermore, patients with inactive inflamma-
tion at the outset of treatment were able to maintain disease 
quiescence with an acceptable side effect profile.
Evidence is also beginning to support the use of adali-
mumab in uveitis. Adalimumab is a humanized monoclonal 
antibody against soluble and membrane-bound TNF, which 
has the advantage of being a subcutaneous injection that 
patients can perform at home, rather than requiring hospital 
admission for intravenous infusions.64
Novel biologic agents
Daclizumab is a humanized immunoglobulin G monoclo-
nal antibody directed against the CD25 subunit of the IL-2 
receptor complex that has been shown to be effective in 
suppressing intraocular inflammation. IL-2 receptors are 
expressed  on the cell membranes of activated T-cells, and 
significant increases in IL-2 levels have been detected in the 
aqueous humor of patients with BSCR.21 A pilot study has 
demonstrated that twice-weekly treatments with daclizumab 
are effective in  controlling intraocular inflammation and sta-
bilizing visual acuity in BSCR patients who were intolerant 
to conventional immunosuppressive therapy, although some 
patients still experienced ongoing deterioration of their ERG 
parameters.65
In terms of the IL-17 pathway, secukinumab is a human 
monoclonal antibody directed against IL-17 that failed to 
demonstrate efficacy in early trials in uveitis, but which 
may hold some promise for more targeted patient groups.23 
Ustekinumab targets the p40 subunit of IL-23 and IL-12, 
and IL-12, hence targeting the Th17 and Th1 pathways. 
This has been approved for psoriasis, but there is as yet 
no data for BSCR or other types of uveitis.22 Nevertheless, 
this may be a promising therapeutic approach and provides 
hope for interrupting a mechanism that may be involved in 
the generation of tolerance.66 Similarly, IL-6 is involved in 
the pathogenesis of experimental autoimmune uveitis and 
is necessary for the generation of local and systemic Th17 
responses in animal models of disease.67 IL-6 is blocked by 
tocilizumab, and several case reports have now demonstrated 
its efficacy in the treatment of uveitis refractory to anti-TNF, 
including cases of BSCR.68
Other novel systemic approaches include reducing anti-
gen presentation by blocking lymph node efflux via the sphin-
gosine-1-phosphate receptor (fingolimod)69 and reducing 
inflammatory cell migration via α4-integrin (natalizumab).70 
There is as yet no evidence for either of these in BSCR.
Other systemic  
immunomodulatory agents
Intravenous immunoglobulin is a therapeutic preparation of 
human immunoglobulin G obtained from the pooled plasma 
of healthy individuals that can be used to treat a number of 
autoimmune conditions, including uveitis. The mechanisms 
of action are complicated and include effects on both the 
innate and adaptive immune systems.71 One study has shown 
efficacy in the treatment of refractory BSCR.72
Interferons (IFNs) possess antiviral, anti-proliferative, 
and immunomodulatory properties.73 interferon-α2a is the 
type most commonly administered in uveitis, and is normally 
produced by dendritic cells in response to viral infection, 
stimulating the activity of NK and T cytotoxic cells and 
increasing the expression of Major Histocompatability Com-
plex (MHC) class I. It is administered subcutaneously and the 
majority of its use has been in uveitis associated with Behcet’s 
disease, although it has also been used with some success in 
BSCR.74 Unfortunately, it has many side effects, especially 
flu-like symptoms, which can be debilitating.
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Local therapy
In addition to oral treatment, local therapy can be useful in 
managing acute exacerbations of the disease, in particular 
these affecting only one eye or in cases of asymmetric 
involvement.75 Both periocular and intravitreal corticoster-
oids have been used. Periocular corticosteroid injections are 
safe, with a low risk of complications,76–78 but intravitreal 
therapy is more effective, and triamcinolone is the intrav-
itreal corticosteroid of choice. However, raised intraocular 
pressure occurs in up to 50% of patients within a year,79 
and the rate of cataract progression in greatly increased, 
particularly after several injections.80 More recent develop-
ments include sustained-release corticosteroid implants and 
non-corticosteroid intravitreal therapies.
intravitreal corticosteroid implants
The Ozurdex dexamethasone intravitreal implant (Allergan, 
Irvine, CA, USA) is licensed for the treatment of uveitis, 
and uses a biodegradable polymer delivery system to release 
dexamethasone over about 6 months.81 It is reported to be 
effective in both adult82 and pediatric83 uveitis, but the side 
effect profile of multiple implants is not yet clear and further 
data are needed, including in BSCR.
Retisert (Bausch and Lomb, New Jersey, NY, USA) is an 
intravitreal implant that is surgically placed in the vitreous 
cavity and which releases fluocinolone acetonide to the poste-
rior pole for approximately 2.5 years.84,85 Its efficacy has been 
demonstrated in patients with BSCR,86 but all patients require 
cataract surgery within 3 years87 and up to 40% require trab-
eculectomy surgery.87 Interestingly, BSCR patients are statisti-
cally more likely to require surgery earlier than other patients 
with uveitis.86 There is currently no published evidence for the 
use in uveitis of either the Iluvien fluocinolone implant (Alimera 
Sciences, Alpharetta, GA, USA)88 or the I-vation triamcinolone 
implant (SurModics, Eden Prairie, MN, USA).88,89
intravitreal non-corticosteroid therapy
In order to avoid the side effects of intraocular corticoster-
oids, the use of other agents has expanded in recent years. 
Intraocular methotrexate has been assessed recently in 
uveitis.90,91 In one prospective clinical trial, it was found to 
be effective in reducing posterior segment inflammation,92 
and a larger collaborative series has suggested that it may 
induce longer-term remission in some patients,93 but there is 
no direct evidence for its use in BSCR. Vascular endothelial 
growth factor inhibition has also been essayed as a therapeutic 
approach, but neither bevacizumab nor ranibizumab appear 
particularly effective.94–97
Local inhibition of TNF-α with intraocular infliximab 
appeared a more promising therapeutic direction, but 
clinical trials had mixed results and there has now been a 
call for a moratorium on its use outside of well-designed 
trials,98,99  similar to the case of adalimumab.100,101 However, 
recent preclinical studies of the TNF inhibitor ESBA105 indi-
cate good bioavailability from topical administration,102 
and it may be that this antibody fragment can overcome the 
problems seen with full-size molecules.
Sirolimus, also known as rapamycin, is another potential 
non-corticosteroid therapy. It inhibits the mammalian target 
of rapamycin (mTOR) by binding to the immunophilin FK 
protein 12 (FKBP-12), and thus interrupts T-cell activation 
and proliferation; it also suppresses T-cell proliferation 
through the inhibition of IL-2, IL-4, and IL-15.103 A Phase II 
study of intravitreal and subconjunctival administration of 
sirolimus proved encouraging,104 and the results of Phase III 
trials are awaited.
Future directions
Personalized medicine remains an important goal in the 
therapy of autoimmune conditions including BSCR. The 
variability of prognosis combined with the increasing array 
of treatment options, all with their own side effect profile, 
means that there is considerable value in being able to deter-
mine a patient’s prognosis early in their disease process, and 
to direct their treatment regime accordingly. Similarly, the 
advent of the exquisitely targeted biological agents offers 
the opportunity to tailor therapeutic option to underlying 
immune dysregulation on an individual basis.
For this to be successful, however, patient profiling 
needs to improve. Disease phenotyping is important, as 
are the early detection of disease activity and accurate 
measurement of response to treatment, and advances have 
been made in these areas with the advent of improved 
ocular imaging.
In addition to systemic treatment, local administration of 
drugs remains an attractive option in conditions such as BSCR 
in which there are no systemic disease components. Locally 
delivered corticosteroids have a significant ocular side effect 
profile, so non-corticosteroid options are of particular inter-
est, although it has proved difficult to match the efficacy that 
corticosteroids offer. The hope is that increased understand-
ing of the pathophysiology of uveitis and the mechanisms of 
ocular damage will enable the generation of entirely novel 
therapeutic mechanisms.24,105 For example, improved under-
standing of how inflammasomes potentiate the activation of 
caspase-1 to release IL-1β and IL-18106 leads to the potential 
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for locally delivered anti-IL-1 or anti-caspase-1 therapies,107 
possibly via novel technologies such as antibody fragment or 
short interfering RNA approaches.102,108,109
This advent of novel therapies provides hope for improved 
outcomes in BSCR in the future, but also challenges clini-
cians in terms of directing these therapies appropriately to 
at-risk patients early enough to avoid visual loss, whilst 
minimizing any associated side effects in patients with less 
aggressive disease.
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